News
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
10 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
B of A Securities Maintains Buy on Inozyme Pharma, Lowers Price Target to $14
9 Apr 24
News, Price Target, Analyst Ratings
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
9 Apr 24
News, Price Target, Reiteration, Analyst Ratings
Inozyme Pharma Announces Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
8 Apr 24
News
Top 5 Health Care Stocks That May Plunge In March
28 Mar 24
News, Penny Stocks, Short Ideas, Small Cap, Pre-Market Outlook, Markets, Trading Ideas
Inozyme Pharma To Report Topline Data From Ongoing Phase 1/2 Trials Of INZ-701 In Adults With ABCC6 Deficiency And ENPP1 Deficiency On April 8, 2024
26 Mar 24
Biotech, News, General
HC Wainwright & Co. Maintains Buy on Inozyme Pharma, Maintains $16 Price Target
13 Mar 24
News, Price Target, Analyst Ratings
Inozyme Pharma: Q4 Earnings Insights
12 Mar 24
Earnings
Needham Reiterates Buy on Inozyme Pharma, Maintains $23 Price Target
12 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Inozyme FY23 EPS $(1.37) Vs $(1.78) YoY; Cash, Cash Equivalents, And Short-Term Investments Were $188.6M As Of December 31, 2023
12 Mar 24
Earnings, News
Wedbush Reiterates Outperform on Inozyme Pharma, Maintains $15 Price Target
30 Jan 24
News, Price Target, Reiteration, Analyst Ratings
Press releases
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
8 Apr 24
Press Releases
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 Apr 24
Press Releases
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
2 Apr 24
News, Press Releases
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
26 Mar 24
Biotech, Press Releases, General
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights
12 Mar 24
Earnings, Press Releases
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference
26 Feb 24
News, Health Care, Press Releases
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6 Feb 24
Press Releases